PE20171736A1 - Derivados de 3-(4'-sustituido)-bencil-eter de pregnenolona - Google Patents

Derivados de 3-(4'-sustituido)-bencil-eter de pregnenolona

Info

Publication number
PE20171736A1
PE20171736A1 PE2017001377A PE2017001377A PE20171736A1 PE 20171736 A1 PE20171736 A1 PE 20171736A1 PE 2017001377 A PE2017001377 A PE 2017001377A PE 2017001377 A PE2017001377 A PE 2017001377A PE 20171736 A1 PE20171736 A1 PE 20171736A1
Authority
PE
Peru
Prior art keywords
pregnenolone
benzyl
derivatives
ether
substituted
Prior art date
Application number
PE2017001377A
Other languages
English (en)
Inventor
Pier Vincenzo Piazza
Monique Vallee
Francois-Xavier Felpin
Jean-Michel Revest
Sandy Fabre
Original Assignee
Inserm (Institut National De La Sante Et De La Rech Medicale)
Alienor Farma
Univ Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47278185&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20171736(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inserm (Institut National De La Sante Et De La Rech Medicale), Alienor Farma, Univ Bordeaux filed Critical Inserm (Institut National De La Sante Et De La Rech Medicale)
Publication of PE20171736A1 publication Critical patent/PE20171736A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE PREGNENOLONA DE FORMULA (I) DONDE R1 ES ALQUILO C1-8, ALCOXI C1-8, CN, NO2, AMINO, COOH, COOCH3, OH, N3 O HALOGENO; R2 ES H, OH, ALQUILO C1-8, ALCOXI C1-8, ALQUENILO C2-6, HALOGENO, BENCILO OPCIONALMENTE SUSTITUIDO O FENILO OPCIONALMENTE SUSTITUIDO. SON COMPUESTOS PREFERIDOS: 3-(p-HIDROXIBENCILOXI)-PREGNENOLONA; 3-(p-METILBENCILOXI)-PREGNENOLONA; 3-(p-ETILBENCILOXI)-PREGNENOLONA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DEL RECEPTOR CB1 SIENDO UTILES EN EL TRATAMIENTO DE ESTEATOSIS, NEFROPATIAS, GLAUCOMA
PE2017001377A 2012-11-28 2013-11-27 Derivados de 3-(4'-sustituido)-bencil-eter de pregnenolona PE20171736A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12194704 2012-11-28

Publications (1)

Publication Number Publication Date
PE20171736A1 true PE20171736A1 (es) 2017-12-04

Family

ID=47278185

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015000680A PE20151557A1 (es) 2012-11-28 2013-11-27 Derivados de 3-(4'-sustituido)-bencil-eter de pregnenolona
PE2017001377A PE20171736A1 (es) 2012-11-28 2013-11-27 Derivados de 3-(4'-sustituido)-bencil-eter de pregnenolona

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2015000680A PE20151557A1 (es) 2012-11-28 2013-11-27 Derivados de 3-(4'-sustituido)-bencil-eter de pregnenolona

Country Status (24)

Country Link
US (4) US10259839B2 (es)
EP (2) EP2925770B1 (es)
JP (1) JP6335915B2 (es)
CN (1) CN105189529B (es)
AU (1) AU2013351190B2 (es)
BR (1) BR112015012194B8 (es)
CA (1) CA2892347C (es)
CL (1) CL2015001438A1 (es)
CY (1) CY1118825T1 (es)
DK (1) DK2925770T3 (es)
ES (1) ES2621528T3 (es)
HR (1) HRP20170503T1 (es)
HU (1) HUE032190T2 (es)
LT (1) LT2925770T (es)
MX (1) MX349703B (es)
NZ (1) NZ708086A (es)
PE (2) PE20151557A1 (es)
PL (1) PL2925770T3 (es)
PT (1) PT2925770T (es)
RS (1) RS55803B1 (es)
RU (1) RU2667065C2 (es)
SI (1) SI2925770T1 (es)
WO (1) WO2014083068A1 (es)
ZA (1) ZA201503326B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2709631T (pt) 2011-05-20 2017-04-19 Inserm - Inst Nat De La Santé Et De La Rech Médicale Antagonistas de receptor de cb1
DK3755339T3 (da) 2018-02-20 2024-02-26 Aelis Farma 3-beta-(4-methoxybenzyloxy)pregn-5-en-20-on til anvendelse i behandlingen af cannabinoid-relaterede lidelser
EP3669876A1 (en) * 2018-12-18 2020-06-24 Aelis Farma 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE972443C (de) * 1952-12-18 1959-10-15 Ciba Geigy Hautpflegemittel
US3244696A (en) 1959-04-30 1966-04-05 Oletta Sa Extraction of alkaloids from plants of genus holarrhena
US3084174A (en) 1960-11-17 1963-04-02 Merck & Co Inc 3-enol ethers of delta-steroids
DE1166189B (de) 1961-09-01 1964-03-26 Merck Ag E Verfahren zur Herstellung von 3ª‰-Fluor-í¸-steroiden
US3169133A (en) 1962-07-02 1965-02-09 Upjohn Co 3alpha-fluoroandrostanes and 15beta-fluorogesterone
US3361744A (en) 1962-07-18 1968-01-02 American Cyanamid Co Novel 17-hydrocarbon substituted progesterones, intermediates and methods of preparing the same
US3351639A (en) 1963-03-20 1967-11-07 American Cyanamid Co 17-alkyl-20-keto substituted pregnenes, pregnadienes and methods of preparing the same
US4622317A (en) 1984-08-16 1986-11-11 University Of Miami Treatment of skin over androgenicity using compositions containing pregnenolone
US4628052A (en) 1985-05-28 1986-12-09 Peat Raymond F Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities
US5226943A (en) 1986-08-20 1993-07-13 Akzo N.V. Herbicides and fungicides containing activity promoting additives
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5175154A (en) 1987-11-25 1992-12-29 Research Corporation Technologies, Inc. 5 α-pregnan-20-ones and 5-pregnen-20-ones and related compounds
US4933157A (en) * 1988-06-27 1990-06-12 The University Of Michigan Radioiodinated arylaliphatic ether analogues of cholesterol
KR100249555B1 (ko) 1991-06-18 2000-04-01 루게쥐농 프랑스와 스테로이드를 함유하는 안구용 조성물, 및 녹내장 치료에 이들 조성물을 사용하는 방법
US5763431A (en) 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
US6117860A (en) 1994-08-04 2000-09-12 Pherin Pharmaceuticals, Inc. Steroids as neurochemical stimulators of the VNO to treat paroxistic tachycardia
US5994334A (en) 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
US6056972A (en) 1997-02-26 2000-05-02 Dimera, Llc Method for reducing coronary artery reactivity
US5968918A (en) 1997-10-17 1999-10-19 Kanda; Iwao Method for the prevention of coronary artery spasm
AU756001B2 (en) 1998-03-11 2003-01-02 Umecrine Mood Ab Epiallopregnanolone in the treatment of CNS disorders
US6579862B1 (en) 1999-01-12 2003-06-17 Council Of Scientific & Industrial Research Method of treating hyperlipidemic and hyperglycemic conditions in mammals using pregnadienols and pregnadienones
US6610674B1 (en) 1999-09-28 2003-08-26 University Of Pennsylvania Method of treating inflammatory conditions with progesterone analogs
US20030125311A1 (en) 2000-03-17 2003-07-03 Etienne-Emile Baulieu Compounds capable of binding with the cytoskeleton
EP1347763A4 (en) 2000-11-06 2005-10-12 Univ Boston NEURACTIVE STEROID DERIVATIVES AND METHOD FOR THEIR USE
SE0100857D0 (sv) 2001-03-13 2001-03-13 Tomas Hagstroem Treatment of tumors
US20030045514A1 (en) 2001-05-03 2003-03-06 Louis Monti 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors
WO2003045362A2 (en) 2001-11-30 2003-06-05 Solvay Pharmaceuticals Gmbh Treatment of th1 dominated immunological disease states with non-endogenous gestagen compounds
SE0104423D0 (sv) 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
FR2850023B1 (fr) 2003-01-17 2007-04-06 Mapreg Medicaments pour le systeme nerveux
KR20050023998A (ko) 2003-09-04 2005-03-10 주식회사 코오롱 소화성 궤양 치료제
AU2005259499A1 (en) 2004-06-29 2006-01-12 Jado Technologies Gmbh Use of steroid-derived pharmaceutical compositions for treating disorders relating to pathological processes in lipid rafts
US8604011B2 (en) 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
EP1841778B1 (en) 2005-01-18 2012-03-14 Abbott Products GmbH Method for preparing medrogestone
US8080538B2 (en) 2006-07-12 2011-12-20 Smith Edwin B Method for increasing absorption of steroid hormones
US7960553B1 (en) * 2006-10-02 2011-06-14 Florida State University Research Founation, Inc. Reagent for synthesis of para-methoxbenzyl (PMB) ethers and associated methods
EP2097437B1 (en) * 2006-11-21 2015-05-27 Umecrine Cognition AB The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders
US20090203658A1 (en) * 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
US20080171728A1 (en) 2007-01-12 2008-07-17 Quatrx Pharmaceuticals Co. Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone
US20120142645A1 (en) 2009-03-17 2012-06-07 Marx Christine E Neuroactive steroid compositions and methods of use for lowering cholesterol
CZ303037B6 (cs) 2009-05-28 2012-03-07 Ústav organické chemie a biochemie, Akademie ved CR, v. v. i. Deriváty pregnanolonu substituované v poloze 3alfa, zpusob jejich výroby a jejich použití
EP2566482A1 (en) * 2010-05-07 2013-03-13 Institut National de la Santé et de la Recherche Médicale Progesterone receptor antagonists and uses thereof
PT2709631T (pt) * 2011-05-20 2017-04-19 Inserm - Inst Nat De La Santé Et De La Rech Médicale Antagonistas de receptor de cb1

Also Published As

Publication number Publication date
WO2014083068A1 (en) 2014-06-05
CA2892347A1 (en) 2014-06-05
AU2013351190B2 (en) 2018-03-29
CN105189529A (zh) 2015-12-23
HRP20170503T1 (hr) 2017-06-16
NZ708086A (en) 2020-04-24
US10259839B2 (en) 2019-04-16
CL2015001438A1 (es) 2015-10-23
CY1118825T1 (el) 2018-01-10
RU2015125568A (ru) 2017-01-10
US20150284423A1 (en) 2015-10-08
US20170226148A1 (en) 2017-08-10
RU2667065C2 (ru) 2018-09-14
LT2925770T (lt) 2017-06-26
BR112015012194B8 (pt) 2022-11-22
CA2892347C (en) 2019-04-02
JP6335915B2 (ja) 2018-05-30
EP2925770A1 (en) 2015-10-07
ZA201503326B (en) 2016-11-30
PL2925770T3 (pl) 2017-07-31
BR112015012194A2 (pt) 2017-07-11
MX349703B (es) 2017-08-08
EP3176176A1 (en) 2017-06-07
US20210230211A1 (en) 2021-07-29
EP2925770B1 (en) 2017-01-18
DK2925770T3 (en) 2017-04-10
AU2013351190A1 (en) 2015-05-21
JP2016501871A (ja) 2016-01-21
PT2925770T (pt) 2017-04-13
BR112015012194B1 (pt) 2022-10-25
ES2621528T3 (es) 2017-07-04
HUE032190T2 (en) 2017-09-28
SI2925770T1 (sl) 2017-07-31
CN105189529B (zh) 2017-09-05
MX2015006724A (es) 2016-01-14
US20190202857A1 (en) 2019-07-04
PE20151557A1 (es) 2015-11-18
RS55803B1 (sr) 2017-08-31

Similar Documents

Publication Publication Date Title
CY1119499T1 (el) Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglur2
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
EA201390934A1 (ru) Композиции и способы модулирования fxr
CY1118721T1 (el) Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης
EA201501122A8 (ru) Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4)
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
PE20160665A1 (es) Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x
CY1118362T1 (el) Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
PE20150627A1 (es) Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso
PE20141598A1 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
CY1118541T1 (el) D2 αποκλειστες, μεθοδοι συνθεσης και μεθοδοι χρησης
MX2013002329A (es) Agonista de receptores de neutrofina y sus usos como medicamentos.
MX2013001234A (es) Derivados deuterados de tandospirona como agonistas del receptor 5-hidroxitriptamina 1a.
PE20151782A1 (es) Derivados de azaquinolin-carboxamida
EA201490031A1 (ru) Циклоалкил-конденсированные тетрагидрохинолины в качестве модуляторов рецепторов crth
EA201491227A1 (ru) Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2
EA201001882A1 (ru) Гидроксизамещенные тиенопиримидиноны как антагонисты рецептора-i меланинконцентрирующего гормона
EA201290229A1 (ru) Производные спиролактама и их применение
PE20171736A1 (es) Derivados de 3-(4'-sustituido)-bencil-eter de pregnenolona

Legal Events

Date Code Title Description
FG Grant, registration